- Home
- USEA vs KPRX Comparison
USEA vs KPRX Comparison
Compare USEA & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- KPRX
- Stock Information
- Founded
- USEA 2004
- KPRX 1998
- Country
- USEA Greece
- KPRX United States
- Employees
- USEA N/A
- KPRX N/A
- Industry
- USEA Marine Transportation
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- USEA Consumer Discretionary
- KPRX Health Care
- Exchange
- USEA Nasdaq
- KPRX Nasdaq
- Market Cap
- USEA 10.5M
- KPRX 9.2M
- IPO Year
- USEA N/A
- KPRX N/A
- Fundamental
- Price
- USEA $1.70
- KPRX $2.66
- Analyst Decision
- USEA
- KPRX Strong Buy
- Analyst Count
- USEA 0
- KPRX 1
- Target Price
- USEA N/A
- KPRX $10.00
- AVG Volume (30 Days)
- USEA 22.3K
- KPRX 53.1K
- Earning Date
- USEA 08-06-2025
- KPRX 11-07-2025
- Dividend Yield
- USEA 2.37%
- KPRX N/A
- EPS Growth
- USEA N/A
- KPRX N/A
- EPS
- USEA N/A
- KPRX N/A
- Revenue
- USEA $42,625,000.00
- KPRX N/A
- Revenue This Year
- USEA N/A
- KPRX N/A
- Revenue Next Year
- USEA N/A
- KPRX N/A
- P/E Ratio
- USEA N/A
- KPRX N/A
- Revenue Growth
- USEA N/A
- KPRX N/A
- 52 Week Low
- USEA $1.00
- KPRX $2.25
- 52 Week High
- USEA $2.78
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- USEA 61.69
- KPRX 46.48
- Support Level
- USEA $1.66
- KPRX $2.60
- Resistance Level
- USEA $1.78
- KPRX $2.80
- Average True Range (ATR)
- USEA 0.05
- KPRX 0.12
- MACD
- USEA 0.00
- KPRX -0.00
- Stochastic Oscillator
- USEA 63.64
- KPRX 19.09
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.